NASDAQ:IMMX Immix Biopharma - IMMX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.63 +0.03 (+1.15%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.42▼$2.7150-Day Range$1.05▼$2.6352-Week Range$0.68▼$5.37Volume134,726 shsAverage Volume256,716 shsMarket Capitalization$36.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immix Biopharma MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingAcquiring Shares$5,200 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector804th out of 1,053 stocksPharmaceutical Preparations Industry402nd out of 519 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Immix Biopharma. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.93% of the float of Immix Biopharma has been sold short.Short Interest Ratio / Days to CoverImmix Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immix Biopharma has recently decreased by 19.24%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmix Biopharma does not currently pay a dividend.Dividend GrowthImmix Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMX. Previous Next 2.8 News and Social Media Coverage News SentimentImmix Biopharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Immix Biopharma this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,200.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.30% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.15% of the stock of Immix Biopharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immix Biopharma are expected to decrease in the coming year, from ($0.43) to ($0.63) per share.Price to Book Value per Share RatioImmix Biopharma has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immix Biopharma (NASDAQ:IMMX) StockImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Read More Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMX Stock News HeadlinesJanuary 26, 2023 | seekingalpha.comIMMX Immix Biopharma, Inc.January 13, 2023 | finance.yahoo.comImmix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 6, 2023 | finance.yahoo.comImmix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet ReachedDecember 28, 2022 | finance.yahoo.comNexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell MeetingDecember 20, 2022 | finance.yahoo.comImmix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialDecember 19, 2022 | finance.yahoo.comImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid TumorsDecember 15, 2022 | marketwatch.comImmix Biopharma Shares Surge 61% On Positive Rates for Multiple Myeloma, AL Amyloidosis DrugFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 14, 2022 | finance.yahoo.comImmix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses)December 13, 2022 | finance.yahoo.comWe're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash WiselyDecember 12, 2022 | finance.yahoo.comImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient DosingNovember 11, 2022 | finance.yahoo.comImmix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review VoucherOctober 25, 2022 | finance.yahoo.comImmix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26October 18, 2022 | finance.yahoo.comImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead SiteSeptember 20, 2022 | uk.finance.yahoo.comImmix Biopharma (IMMX): Initiation — Fresh faces with a unique tissue-targeting therapySeptember 19, 2022 | markets.businessinsider.comImmix Biopharma (IMMX): Initiation Fresh faces with a unique tissue-targeting therapySeptember 14, 2022 | nasdaq.comImmix Biopharma, Inc.'s (NASDAQ:IMMX) recent US$2.9m market cap decline means a loss of US$194k for insiders who bought this yearSeptember 7, 2022 | finance.yahoo.comImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical TrialsAugust 23, 2022 | finance.yahoo.comInsiders who bought in the last 12 months lose an additional US$175k as Immix Biopharma, Inc. (NASDAQ:IMMX) drops to US$28mJune 4, 2022 | seekingalpha.comImmix, Bright Green top healthcare gainers; while Zosano, Immunic lead losers' packJune 3, 2022 | seekingalpha.comIMMX, ZY and SCOR among premarket gainersMay 21, 2022 | marketwatch.comImmix Soars on Study ResultsMay 21, 2022 | nz.finance.yahoo.comWe Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business GrowthMay 20, 2022 | marketwatch.comImmix Biopharma Shares 49% Higher After Data in Connective Tissue Cancer Mice StudyMay 20, 2022 | seekingalpha.comImmixBio surges on mice data for lead candidate in connective tissue cancerMay 20, 2022 | nasdaq.comImmixBio: IMX-110 Shows Improved Survival In Connective Tissue Cancer Soft Tissue Sarcoma Mice StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMX Company Calendar Last Earnings11/09/2022Today2/01/2023Next Earnings (Estimated)2/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMMX CUSIPN/A CIK1873835 Webwww.immixbio.com Phone310-651-8041FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-149.98% Return on Assets-145.58% Debt Debt-to-Equity RatioN/A Current Ratio26.92 Quick Ratio26.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book1.93Miscellaneous Outstanding Shares13,930,000Free Float6,782,000Market Cap$36.64 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Ilya Rachman M.B.A. (Age 50)M.D., MBA, Ph.D., Co-Founder, Chairman & CEO Comp: $193.31kMr. Gabriel Morris B.A. (Age 36)CFO & Director Comp: $100kMr. Sean Senn J.D.M.B.A., M.Sc., MBA, MSc, Co-FounderDr. Vladimir P. Torchilin D.Sc. (Age 76)MSE, Ph.D., Scientific Co-Founder Mr. Ben H. Lyon J.D.Exec. VP & Gen. CounselDr. Graham Ross FFPM (Age 63)M.D., Acting Chief Medical Officer & Head of Clinical Devel. Mr. Nandan Oza B.S. (Age 61)Head of Chemistry, Manufacturing & Control More ExecutivesKey CompetitorsEquilliumNASDAQ:EQAcasti PharmaNASDAQ:ACSTMarker TherapeuticsNASDAQ:MRKRTFF PharmaceuticalsNASDAQ:TFFPMoleculin BiotechNASDAQ:MBRXView All CompetitorsInsiders & InstitutionsBank of Montreal CanBought 15,000 shares on 2/1/2023Ownership: 0.108%Vanguard Group Inc.Bought 54,220 shares on 11/15/2022Ownership: 0.755%Ilya M RachmanBought 5,200 shares on 11/14/2022Total: $5,200.00 ($1.00/share)Renaissance Technologies LLCBought 27,050 shares on 11/14/2022Ownership: 0.194%Sean SennSold 200 sharesTotal: $550.00 ($2.75/share)View All Insider TransactionsView All Institutional Transactions IMMX Stock - Frequently Asked Questions Should I buy or sell Immix Biopharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immix Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IMMX shares. View IMMX analyst ratings or view top-rated stocks. How have IMMX shares performed in 2023? Immix Biopharma's stock was trading at $2.29 at the beginning of the year. Since then, IMMX shares have increased by 14.8% and is now trading at $2.63. View the best growth stocks for 2023 here. Are investors shorting Immix Biopharma? Immix Biopharma saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 172,900 shares, a decrease of 19.2% from the December 31st total of 214,100 shares. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 0.2 days. Approximately 2.9% of the shares of the stock are short sold. View Immix Biopharma's Short Interest. When is Immix Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023. View our IMMX earnings forecast. How were Immix Biopharma's earnings last quarter? Immix Biopharma, Inc. (NASDAQ:IMMX) announced its earnings results on Wednesday, November, 9th. The company reported ($0.11) EPS for the quarter. When did Immix Biopharma IPO? (IMMX) raised $23 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share. What is Immix Biopharma's stock symbol? Immix Biopharma trades on the NASDAQ under the ticker symbol "IMMX." Who are Immix Biopharma's major shareholders? Immix Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.11%). Insiders that own company stock include Ilya M Rachman and Sean Senn. View institutional ownership trends. How do I buy shares of Immix Biopharma? Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immix Biopharma's stock price today? One share of IMMX stock can currently be purchased for approximately $2.63. How much money does Immix Biopharma make? Immix Biopharma (NASDAQ:IMMX) has a market capitalization of $36.64 million. How can I contact Immix Biopharma? The official website for the company is www.immixbio.com. The company can be reached via phone at 310-651-8041. This page (NASDAQ:IMMX) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.